Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T cells produce complete responses in T-cell malignancies

Publish date:: January 7, 2020

Key clinical point: Anti-CD5 chimeric antigen receptor (CAR) T cells can produce complete responses (CRs) in patients with relapsed/refractory T-cell malignancies.

Major finding: Three patients achieved a CR after CAR T-cell therapy, and one patient achieved a mixed response that deepened to a CR after transplant.

Study details: A phase 1 trial of 11 treated patients.

Disclosures: The trial is sponsored by Baylor College of Medicine. Dr. Hill reported having no conflicts of interest.

Citation:

Hill L et al. ASH 2019, Abstract 199.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry,

Study: Complications from childhood ALL and its treatment are common, but can be managed,

All Specialties